In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00. The company’s shares closed yesterday at DKK597.63.

For Novo Nordisk A/S investors (NVO), things couldn't have gotten to a worse start this week. Just when the market was preparing for a bottom, as NVO has been consolidating constructively over the ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

Pre-season testing for the 2025 F1 season starts in Bahrain at the Bahrain International Circuit from Wednesday to Friday. Ten teams will fine-tune their new cars over three days. Fans can look ...